{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:44:16Z","timestamp":1790775856821,"version":"4.1.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In Alzheimer\u2019s disease (AD), amyloid-\u03b2 1\u201342 (A\u03b242) neurotoxicity stems mostly from its soluble oligomeric aggregates. Studies of such aggregates have been hampered by the lack of oligomer-specific research tools and their intrinsic instability and heterogeneity. Here, we developed a monoclonal antibody with a unique oligomer-specific binding profile (ALZ-201) using oligomer-stabilising technology. Subsequently, we assessed the etiological relevance of the A\u03b2 targeted by ALZ-201 on physiologically derived, toxic A\u03b2 using extracts from post-mortem brains of AD patients and controls in primary mouse neuron cultures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Mice were immunised with stable oligomers derived from the A\u03b242 peptide with A21C\/A30C mutations (A\u03b2CC), and ALZ-201 was developed using hybridoma technology. Specificity for the oligomeric form of the A\u03b242CC antigen and A\u03b242 was confirmed using ELISA, and non-reactivity against plaques by immunohistochemistry (IHC). The antibody\u2019s potential for cross-protective activity against pathological A\u03b2 was evaluated in brain tissue samples from 10 individuals confirmed as AD (<jats:italic>n<\/jats:italic>=7) and non-AD (<jats:italic>n<\/jats:italic>=3) with IHC staining for A\u03b2 and phosphorylated tau (p-Tau) aggregates. Brain extracts were prepared and immunodepleted using the positive control 4G8 antibody, ALZ-201 or an isotype control to ALZ-201. Fractions were biochemically characterised, and toxicity assays were performed in primary mouse neuronal cultures using automated high-content microscopy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>AD brain extracts proved to be more toxic than controls as demonstrated by neuronal loss and morphological determinants (e.g. synapse density and measures of neurite complexity). Immunodepletion using 4G8 reduced A\u03b2 levels in both AD and control samples compared to ALZ-201 or the isotype control, which showed no significant difference. Importantly, despite the differential effect on the total A\u03b2 content, the neuroprotective effects of 4G8 and ALZ-201 immunodepletion were similar, whereas the isotype control showed no effect.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ALZ-201 depletes a toxic species in post-mortem AD brain extracts causing a positive physiological and protective impact on the integrity and morphology of mouse neurons. Its unique specificity indicates that a low-abundant, soluble A\u03b242 oligomer may account for much of the neurotoxicity in AD. This critical attribute identifies the potential of ALZ-201 as a novel drug candidate for achieving a true, clinical therapeutic effect in AD.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13195-022-01141-1","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T04:26:03Z","timestamp":1672287963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A\u03b242 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer\u2019s disease brain extracts"],"prefix":"10.1186","volume":"14","author":[{"given":"Anders","family":"Sandberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Berenjeno-Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Crespo","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Axenhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia Schedin","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Batenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J. M.","family":"Hoozemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars O.","family":"Tjernberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiep","family":"Scheper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"1141_CR1","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1126\/science.1197623","volume":"330","author":"KG Mawuenyega","year":"2010","unstructured":"Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science. 2010;330:1774.","journal-title":"Science."},{"key":"1141_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8:595\u2013608.","journal-title":"EMBO Mol Med."},{"key":"1141_CR3","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/19083","volume":"398","author":"B De Strooper","year":"1999","unstructured":"De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518\u201322.","journal-title":"Nature."},{"key":"1141_CR4","doi-asserted-by":"publisher","first-page":"189ra77","DOI":"10.1126\/scitranslmed.3005615","volume":"5","author":"R Potter","year":"2013","unstructured":"Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, et al. Increased in vivo amyloid-\u03b242 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5:189ra77.","journal-title":"Sci Transl Med."},{"issue":"8","key":"1141_CR5","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2(8):864\u201370.","journal-title":"Nat Med."},{"key":"1141_CR6","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1073\/pnas.94.5.2025","volume":"94","author":"T Tomita","year":"1997","unstructured":"Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci U S A. 1997;94:2025\u201330.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1141_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488:96\u20139.","journal-title":"Nature."},{"key":"1141_CR8","doi-asserted-by":"publisher","first-page":"30990","DOI":"10.1074\/jbc.M114.589069","volume":"289","author":"JA Maloney","year":"2014","unstructured":"Maloney JA, Bainbridge T, Gustafson A, Zhang S, Kyauk R, Steiner P, et al. Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. J Biol Chem. 2014;289:30990\u20131000.","journal-title":"J Biol Chem."},{"key":"1141_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimers Res Ther. 2019;11:34.","journal-title":"Alzheimers Res Ther."},{"key":"1141_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","volume":"23","author":"GB Frisoni","year":"2022","unstructured":"Frisoni GB, Altomare D, Thal DR, Ribaldi F, van der Kant R, Ossenkoppele R, et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci. 2022;23:53\u201366.","journal-title":"Nat Rev Neurosci."},{"key":"1141_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom GS. Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71:505\u20138.","journal-title":"JAMA Neurol."},{"key":"1141_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00401-016-1632-3","volume":"132","author":"DJ Koss","year":"2016","unstructured":"Koss DJ, Jones G, Cranston A, Gardner H, Kanaan NM, Platt B. Soluble pre-fibrillar tau and \u03b2-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline. Acta Neuropathol. 2016;132:875\u201395.","journal-title":"Acta Neuropathol."},{"key":"1141_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/1073858418791128","volume":"25","author":"SV Ovsepian","year":"2019","unstructured":"Ovsepian SV, O'Leary VB, Zaborszky L, Ntziachristos V, Dolly JO. Amyloid plaques of Alzheimer's disease as hotspots of glutamatergic activity. Neuroscientist. 2019;25:288\u201397.","journal-title":"Neuroscientist."},{"key":"1141_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3233\/JAD-2010-1221","volume":"19","author":"MP Murphy","year":"2010","unstructured":"Murphy MP, LeVine H 3rd. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis. 2010;19:311\u201323.","journal-title":"J Alzheimers Dis."},{"key":"1141_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nsmb.1799","volume":"17","author":"M Ahmed","year":"2010","unstructured":"Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, et al. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol. 2010;17:561\u20137.","journal-title":"Nat Struct Mol Biol."},{"key":"1141_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1073\/pnas.222681699","volume":"100","author":"G Bitan","year":"2003","unstructured":"Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A. 2003;100:330\u20135.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1141_CR17","doi-asserted-by":"publisher","first-page":"10417","DOI":"10.1073\/pnas.1834302100","volume":"100","author":"Y Gong","year":"2003","unstructured":"Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. 2003;100:10417\u201322.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"8","key":"1141_CR18","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1074\/jbc.271.8.4077","volume":"271","author":"Y-M Kuo","year":"1996","unstructured":"Kuo Y-M, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, et al. Water-soluble A\u03b2 (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996;271(8):4077\u201381.","journal-title":"J Biol Chem."},{"key":"1141_CR19","doi-asserted-by":"publisher","first-page":"e32014","DOI":"10.1371\/journal.pone.0032014","volume":"7","author":"D Sehlin","year":"2012","unstructured":"Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, et al. Large aggregates are the major soluble A\u03b2 species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012;7:e32014.","journal-title":"PLoS One."},{"key":"1141_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/archneur.56.6.673","volume":"56","author":"N Andreasen","year":"1999","unstructured":"Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56:673\u201380.","journal-title":"Arch Neurol."},{"key":"1141_CR21","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","volume":"34","author":"MJ Savage","year":"2014","unstructured":"Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, et al. A sensitive A\u03b2 oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. J Neurosci. 2014;34:2884\u201397.","journal-title":"J Neurosci."},{"key":"1141_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2017.08.007","volume":"110","author":"AE Roher","year":"2017","unstructured":"Roher AE, Kokjohn TA, Clarke SG, Sierks MR, Maarouf CL, Serrano GE, et al. APP\/A\u03b2 structural diversity and Alzheimer's disease pathogenesis. Neurochem Int. 2017;110:1\u201313.","journal-title":"Neurochem Int."},{"key":"1141_CR23","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/acel.12521","volume":"15","author":"A Wyssenbach","year":"2016","unstructured":"Wyssenbach A, Quintela T, Llavero F, Zugaza JL, Matute C, Alberdi E. Amyloid \u03b2-induced astrogliosis is mediated by \u03b21-integrin via NADPH oxidase 2 in Alzheimer's disease. Aging Cell. 2016;15:1140\u201352.","journal-title":"Aging Cell."},{"key":"1141_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2741\/s265","volume":"4","author":"SS Yan","year":"2012","unstructured":"Yan SS, Chen D, Yan S, Guo L, Du H, Chen JX. RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease. Front Biosci (Schol Ed). 2012;4:240\u201350.","journal-title":"Front Biosci (Schol Ed)."},{"key":"1141_CR25","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","volume":"155","author":"LF Lue","year":"1999","unstructured":"Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853\u201362.","journal-title":"Am J Pathol."},{"key":"1141_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101\u201312.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"1141_CR27","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","volume":"46","author":"CA McLean","year":"1999","unstructured":"McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860\u20136.","journal-title":"Ann Neurol."},{"key":"1141_CR28","doi-asserted-by":"publisher","first-page":"10191","DOI":"10.1523\/JNEUROSCI.3432-04.2004","volume":"24","author":"PN Lacor","year":"2004","unstructured":"Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 2004;24:10191\u2013200.","journal-title":"J Neurosci."},{"key":"1141_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/JAD-142136","volume":"45","author":"W Jongbloed","year":"2015","unstructured":"Jongbloed W, Bruggink KA, Kester MI, Visser PJ, Scheltens P, Blankenstein MA, et al. Amyloid-\u03b2 oligomers relate to cognitive decline in Alzheimer's disease. J Alzheimers Dis. 2015;45:35\u201343.","journal-title":"J Alzheimers Dis."},{"key":"1141_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fncel.2015.00191","volume":"9","author":"ST Ferreira","year":"2015","unstructured":"Ferreira ST, Lourenco MV, Oliveira MM, De Felice FG. Soluble amyloid-\u03b2 oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease. Front Cell Neurosci. 2015;9:191.","journal-title":"Front Cell Neurosci."},{"key":"1141_CR31","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1006\/exnr.1999.7085","volume":"158","author":"J Wang","year":"1999","unstructured":"Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol. 1999;158:328\u201337.","journal-title":"Exp Neurol."},{"key":"1141_CR32","doi-asserted-by":"publisher","first-page":"522073","DOI":"10.3389\/fnmol.2020.552073","volume":"13","author":"B Calvo-Flores Guzm\u00e1n","year":"2020","unstructured":"Calvo-Flores Guzm\u00e1n B, Elizabeth Chaffey T, Hansika Palpagama T, Waters S, Boix J, Tate WP, et al. The interplay between beta-amyloid 1-42 (A\u03b2(1-42))-induced hippocampal inflammatory response, p-tau, vascular pathology, and their synergistic contributions to neuronal death and behavioral deficits. Front Mol Neurosci. 2020;13:522073.","journal-title":"Front Mol Neurosci."},{"key":"1141_CR33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ana.22052","volume":"68","author":"S Gandy","year":"2010","unstructured":"Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, et al. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol. 2010;68:220\u201330.","journal-title":"Ann Neurol."},{"key":"1141_CR34","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1074\/jbc.M110.135244","volume":"286","author":"I Maezawa","year":"2011","unstructured":"Maezawa I, Zimin PI, Wulff H, Jin LW. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem. 2011;286:3693\u2013706.","journal-title":"J Biol Chem."},{"key":"1141_CR35","doi-asserted-by":"publisher","first-page":"5161","DOI":"10.1523\/JNEUROSCI.2501-19.2020","volume":"40","author":"M Rolland","year":"2020","unstructured":"Rolland M, Powell R, Jacquier-Sarlin M, Boisseau S, Reynaud-Dulaurier R, Martinez-Hernandez J, et al. Effect of A\u03b2 oligomers on neuronal APP triggers a vicious cycle leading to the propagation of synaptic plasticity alterations to healthy neurons. J Neurosci. 2020;40:5161\u201376.","journal-title":"J Neurosci."},{"key":"1141_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"GM Shankar","year":"2008","unstructured":"Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837\u201342.","journal-title":"Nat Med."},{"key":"1141_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-6-1","volume":"6","author":"CM Sondag","year":"2009","unstructured":"Sondag CM, Dhawan G, Combs CK. Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. J Neuroinflammation. 2009;6:1.","journal-title":"J Neuroinflammation."},{"key":"1141_CR38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1750-1326-9-48","volume":"9","author":"S Tu","year":"2014","unstructured":"Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric A\u03b2-induced synaptic dysfunction in Alzheimer's disease. Mol Neurodegener. 2014;9:48.","journal-title":"Mol Neurodegener."},{"key":"1141_CR39","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/joim.12168","volume":"275","author":"L Lannfelt","year":"2014","unstructured":"Lannfelt L, Relkin NR, Siemers ER. Amyloid-\u00df-directed immunotherapy for Alzheimer's disease. J Intern Med. 2014;275:284\u201395.","journal-title":"J Intern Med."},{"key":"1141_CR40","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312\u201339.","journal-title":"Cell."},{"key":"1141_CR41","first-page":"5341375","volume":"2019","author":"DJ Marciani","year":"2019","unstructured":"Marciani DJ. Promising results from Alzheimer's disease passive immunotherapy support the development of a preventive vaccine. Research (Wash D C). 2019;2019:5341375.","journal-title":"Research (Wash D C)."},{"key":"1141_CR42","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40266-016-0406-x","volume":"33","author":"J Liu","year":"2016","unstructured":"Liu J, Yang B, Ke J, Li W, Suen WC. Antibody-based drugs and approaches against amyloid-\u03b2 species for Alzheimer's disease immunotherapy. Drugs Aging. 2016;33:685\u201397.","journal-title":"Drugs Aging."},{"key":"1141_CR43","doi-asserted-by":"publisher","first-page":"6751","DOI":"10.3390\/molecules27196751","volume":"27","author":"C Song","year":"2022","unstructured":"Song C, Zhang T, Zhang Y. Conformational essentials responsible for neurotoxicity of A\u03b242 aggregates revealed by antibodies against oligomeric A\u03b242. Molecules. 2022;27:6751.","journal-title":"Molecules."},{"key":"1141_CR44","doi-asserted-by":"publisher","first-page":"105010","DOI":"10.1016\/j.nbd.2020.105010","volume":"144","author":"SS Plotkin","year":"2020","unstructured":"Plotkin SS, Cashman NR. Passive immunotherapies targeting A\u03b2 and tau in Alzheimer's disease. Neurobiol Dis. 2020;144:105010.","journal-title":"Neurobiol Dis."},{"key":"1141_CR45","unstructured":"FDA Grants Accelerated Approval for Alzheimer\u2019s Drug [press release]. Food and Drug Administration. 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug Accessed 6 Sept 2022."},{"key":"1141_CR46","doi-asserted-by":"publisher","first-page":"101339","DOI":"10.1016\/j.arr.2021.101339","volume":"68","author":"KI Avgerinos","year":"2021","unstructured":"Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease. Ageing Res Rev. 2021;68:101339.","journal-title":"Ageing Res Rev."},{"key":"1141_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/jnc.15023","volume":"155","author":"S Bullain","year":"2020","unstructured":"Bullain S, Doody R. What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials. J Neurochem. 2020;155:120\u201336.","journal-title":"J Neurochem."},{"key":"1141_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79:13\u201321.","journal-title":"JAMA Neurol."},{"key":"1141_CR49","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.neuropharm.2016.03.014","volume":"120","author":"PO Freskg\u00e5rd","year":"2017","unstructured":"Freskg\u00e5rd PO, Urich E. Antibody therapies in CNS diseases. Neuropharmacology. 2017;120:38\u201355.","journal-title":"Neuropharmacology."},{"key":"1141_CR50","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1073\/pnas.91.12.5705","volume":"91","author":"JF Poduslo","year":"1994","unstructured":"Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci U S A. 1994;91:5705\u20139.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1141_CR51","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s13311-013-0187-4","volume":"10","author":"YJ Yu","year":"2013","unstructured":"Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics. 2013;10:459\u201372.","journal-title":"Neurotherapeutics."},{"key":"1141_CR52","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, et al. Plasma \u03b2-amyloid in Alzheimer's disease and vascular disease. Sci Rep. 2016;6:26801.","journal-title":"Sci Rep."},{"key":"1141_CR53","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:841\u20139.","journal-title":"Alzheimers Dement."},{"key":"1141_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00401-018-1846-7","volume":"136","author":"W Hong","year":"2018","unstructured":"Hong W, Wang Z, Liu W, O'Malley TT, Jin M, Willem M, et al. Diffusible, highly bioactive oligomers represent a critical minority of soluble A\u03b2 in Alzheimer's disease brain. Acta Neuropathol. 2018;136:19\u201340.","journal-title":"Acta Neuropathol."},{"key":"1141_CR55","doi-asserted-by":"publisher","first-page":"534","DOI":"10.4103\/1673-5374.180372","volume":"11","author":"S Balusu","year":"2016","unstructured":"Balusu S, Brkic M, Libert C, Vandenbroucke RE. The choroid plexus-cerebrospinal fluid interface in Alzheimer's disease: more than just a barrier. Neural Regen Res. 2016;11:534\u20137.","journal-title":"Neural Regen Res."},{"key":"1141_CR56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14:133\u201350.","journal-title":"Nat Rev Neurol."},{"key":"1141_CR57","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367\u201385.","journal-title":"Alzheimers Dement."},{"key":"1141_CR58","doi-asserted-by":"publisher","first-page":"862369","DOI":"10.3389\/fneur.2022.862369","volume":"13","author":"CG Withington","year":"2022","unstructured":"Withington CG, Turner RS. Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer's disease. Front Neurol. 2022;13:862369.","journal-title":"Front Neurol."},{"key":"1141_CR59","doi-asserted-by":"publisher","first-page":"9870","DOI":"10.1038\/s41598-019-46306-5","volume":"9","author":"E Gibbs","year":"2019","unstructured":"Gibbs E, Silverman JM, Zhao B, Peng X, Wang J, Wellington CL, et al. A rationally designed humanized antibody selective for amyloid beta oligomers in Alzheimer's disease. Sci Rep. 2019;9:9870.","journal-title":"Sci Rep."},{"key":"1141_CR60","doi-asserted-by":"publisher","first-page":"15595","DOI":"10.1073\/pnas.1001740107","volume":"107","author":"A Sandberg","year":"2010","unstructured":"Sandberg A, Luheshi LM, S\u00f6llvander S, Pereira de Barros T, Macao B, Knowles TP, et al. Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering. Proc Natl Acad Sci U S A. 2010;107:15595\u2013600.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1141_CR61","doi-asserted-by":"publisher","first-page":"22364","DOI":"10.1074\/jbc.272.35.22364","volume":"272","author":"DM Walsh","year":"1997","unstructured":"Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997;272:22364\u201372.","journal-title":"J Biol Chem."},{"key":"1141_CR62","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1042\/BJ20090379","volume":"421","author":"E Cerf","year":"2009","unstructured":"Cerf E, Sarroukh R, Tamamizu-Kato S, Breydo L, Derclaye S, Dufr\u00eane YF, et al. Antiparallel beta-sheet: a signature structure of the oligomeric amyloid beta-peptide. Biochem J. 2009;421:415\u201323.","journal-title":"Biochem J."},{"key":"1141_CR63","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/j.bbamem.2013.04.012","volume":"1828","author":"R Sarroukh","year":"2013","unstructured":"Sarroukh R, Goormaghtigh E, Ruysschaert JM, Raussens V. ATR-FTIR: a \"rejuvenated\" tool to investigate amyloid proteins. Biochim Biophys Acta. 2013;1828:2328\u201338.","journal-title":"Biochim Biophys Acta."},{"key":"1141_CR64","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1472-6750-8-82","volume":"8","author":"B Macao","year":"2008","unstructured":"Macao B, Hoyer W, Sandberg A, Brorsson AC, Dobson CM, H\u00e4rd T. Recombinant amyloid beta-peptide production by coexpression with an affibody ligand. BMC Biotechnol. 2008;8:82.","journal-title":"BMC Biotechnol."},{"key":"1141_CR65","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0091-679X(08)60223-X","volume":"15","author":"RL Davidson","year":"1977","unstructured":"Davidson RL, Gerald PS. Induction of mammalian somatic cell hybridization by polyethylene glycol. Methods Cell Biol. 1977;15:325\u201338.","journal-title":"Methods Cell Biol."},{"key":"1141_CR66","first-page":"210","volume-title":"Antibodies: A Laboratory Manual","author":"ELD Harlow","year":"1998","unstructured":"Harlow ELD. Production of monoclonal antibodies. In: ELD H, NY LD, editors. Antibodies: A Laboratory Manual: Cold Spring Harbor Laboratory; 1998. p. 210\u20133."},{"key":"1141_CR67","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0161-5890(78)90070-6","volume":"15","author":"PL Ey","year":"1978","unstructured":"Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry. 1978;15:429\u201336.","journal-title":"Immunochemistry."},{"key":"1141_CR68","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0022-1759(85)90044-4","volume":"77","author":"B Friguet","year":"1985","unstructured":"Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods. 1985;77:305\u201319.","journal-title":"J Immunol Methods."},{"key":"1141_CR69","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/0161-5890(87)90073-3","volume":"24","author":"FJ Stevens","year":"1987","unstructured":"Stevens FJ. Modification of an ELISA-based procedure for affinity determination: correction necessary for use with bivalent antibody. Mol Immunol. 1987;24:1055\u201360.","journal-title":"Mol Immunol."},{"key":"1141_CR70","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41380-019-0436-y","volume":"26","author":"M Rosato","year":"2021","unstructured":"Rosato M, Stringer S, Gebuis T, Paliukhovich I, Li KW, Posthuma D, et al. Combined cellomics and proteomics analysis reveals shared neuronal morphology and molecular pathway phenotypes for multiple schizophrenia risk genes. Mol Psychiatry. 2021;26:784\u201399.","journal-title":"Mol Psychiatry."},{"key":"1141_CR71","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/BF00201107","volume":"15","author":"NS Greenspan","year":"1993","unstructured":"Greenspan NS, Cooper LJ. Cooperative binding by mouse IgG3 antibodies: implications for functional affinity, effector function, and isotype restriction. Springer Semin Immunopathol. 1993;15:275\u201391.","journal-title":"Springer Semin Immunopathol."},{"key":"1141_CR72","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.7717\/peerj.73","volume":"1","author":"TM Ryan","year":"2013","unstructured":"Ryan TM, Caine J, Mertens HD, Kirby N, Nigro J, Breheney K, et al. Ammonium hydroxide treatment of A\u03b2 produces an aggregate free solution suitable for biophysical and cell culture characterization. PeerJ. 2013;1:e73.","journal-title":"PeerJ."},{"key":"1141_CR73","doi-asserted-by":"publisher","first-page":"e66101","DOI":"10.1371\/journal.pone.0066101","volume":"8","author":"A Dubnovitsky","year":"2013","unstructured":"Dubnovitsky A, Sandberg A, Rahman MM, Benilova I, Lendel C, H\u00e4rd T. Amyloid-\u03b2 protofibrils: size, morphology and synaptotoxicity of an engineered mimic. PLoS One. 2013;8:e66101.","journal-title":"PLoS One."},{"key":"1141_CR74","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1111\/j.1742-4658.2006.05263.x","volume":"273","author":"AS Johansson","year":"2006","unstructured":"Johansson AS, Berglind-Dehlin F, Karlsson G, Edwards K, Gellerfors P, Lannfelt L. Physiochemical characterization of the Alzheimer's disease-related peptides A beta 1-42Arctic and A beta 1-42wt. FEBS J. 2006;273:2618\u201330.","journal-title":"FEBS J."},{"issue":"21","key":"1141_CR75","doi-asserted-by":"publisher","first-page":"12277","DOI":"10.1073\/pnas.95.21.12277","volume":"95","author":"Y Kusumoto","year":"1998","unstructured":"Kusumoto Y, Lomakin A, Teplow DB, Benedek GB. Temperature dependence of amyloid beta-protein fibrillization. Proc Natl Acad Sci U S A. 1998;95(21):12277\u201382.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1141_CR76","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.msec.2014.09.015","volume":"48","author":"KM Batzli","year":"2015","unstructured":"Batzli KM, Love BJ. Agitation of amyloid proteins to speed aggregation measured by ThT fluorescence: a call for standardization. Mater Sci Eng C Mater Biol Appl. 2015;48:359\u201364.","journal-title":"Mater Sci Eng C Mater Biol Appl."},{"key":"1141_CR77","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol."},{"key":"1141_CR78","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement."},{"key":"1141_CR79","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1523\/JNEUROSCI.1698-16.2016","volume":"37","author":"T Yang","year":"2017","unstructured":"Yang T, Li S, Xu H, Walsh DM, Selkoe DJ. Large soluble oligomers of amyloid \u03b2-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J Neurosci. 2017;37:152\u201363.","journal-title":"J Neurosci."},{"key":"1141_CR80","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","volume":"8","author":"JW Arndt","year":"2018","unstructured":"Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2. Sci Rep. 2018;8:6412.","journal-title":"Sci Rep."},{"key":"1141_CR81","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311\u201321.","journal-title":"N Engl J Med."},{"key":"1141_CR82","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322\u201333.","journal-title":"N Engl J Med."},{"key":"1141_CR83","unstructured":"Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer's disease (AD) - other company programmes in AD continue [press release]. Roche 2019. https:\/\/www.roche.com\/media\/releases\/med-cor-2019-01-30 Accessed 6 Sept 2022."},{"key":"1141_CR84","unstructured":"Roche provides update on Alzheimer\u2019s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer\u2019s disease [press release]. Roche. 2022. https:\/\/www.roche.com\/media\/releases\/med-cor-2022-06-16 Accessed 6 Sept 2022."},{"key":"1141_CR85","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","volume":"32","author":"O Adolfsson","year":"2012","unstructured":"Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, et al. An effector-reduced anti-\u03b2-amyloid (A\u03b2) antibody with unique a\u03b2 binding properties promotes neuroprotection and glial engulfment of A\u03b2. J Neurosci. 2012;32:9677\u201389.","journal-title":"J Neurosci."},{"key":"1141_CR86","doi-asserted-by":"publisher","first-page":"39374","DOI":"10.1038\/srep39374","volume":"6","author":"M Ultsch","year":"2016","unstructured":"Ultsch M, Li B, Maurer T, Mathieu M, Adolfsson O, Muhs A, et al. Structure of Crenezumab Complex with A\u03b2 Shows Loss of \u03b2-Hairpin. Sci Rep. 2016;6:39374.","journal-title":"Sci Rep."},{"key":"1141_CR87","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature22809","volume":"546","author":"J Sevigny","year":"2017","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. Addendum: The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease. Nature. 2017;546:564.","journal-title":"Nature."},{"key":"1141_CR88","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","volume":"103","author":"H Englund","year":"2007","unstructured":"Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem. 2007;103:334\u201345.","journal-title":"J Neurochem."},{"key":"1141_CR89","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-A\u03b2 antibody demonstrates sustained cerebral amyloid-\u03b2 binding and elicits cell-mediated removal of human amyloid-\u03b2. J Alzheimers Dis. 2012;28:49\u201369.","journal-title":"J Alzheimers Dis."},{"key":"1141_CR90","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB Demattos","year":"2012","unstructured":"Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, et al. A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer's disease mice. Neuron. 2012;76:908\u201320.","journal-title":"Neuron."},{"key":"1141_CR91","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","volume":"13","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther. 2021;13:98.","journal-title":"Alzheimers Res Ther."},{"key":"1141_CR92","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","volume":"11","author":"G Klein","year":"2019","unstructured":"Klein G, Delmar P, Voyle N, Rehal S, Hofmann C, Abi-Saab D, et al. Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019;11:101.","journal-title":"Alzheimers Res Ther."},{"key":"1141_CR93","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med."},{"key":"1141_CR94","doi-asserted-by":"publisher","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","DOI":"10.1056\/NEJMoa2212948"},{"key":"1141_CR95","unstructured":"Lannfelt LSL, Laudon H, Johannesson M, Sahlin C, Nygren P, F\u00e4lting J, et al. Binding profiles of BAN2401 and aducanumab to different A\u03b2 species. 7 Dec, 2019 CTAD, San Diego. Bioarctic. 2019. https:\/\/www.bioarctic.se\/en\/wp-content\/uploads\/sites\/2\/2019\/12\/binding-profiles-of-ban2401-and-aducanumab-ctad-dec-7-2019.pdf. Accessed 6 Sept 2022."},{"key":"1141_CR96","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40035-021-00258-x","volume":"10","author":"F Rofo","year":"2021","unstructured":"Rofo F, Buijs J, Falk R, Honek K, Lannfelt L, Lilja AM, et al. Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta. Transl Neurodegener. 2021;10:38.","journal-title":"Transl Neurodegener."},{"key":"1141_CR97","unstructured":"Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer\u2019s disease [press release]. Roche. 2022. https:\/\/www.roche.com\/media\/releases\/med-cor-2022-11-14 Accessed 5 Dec 2022."},{"key":"1141_CR98","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S2215-0366(21)00197-8","volume":"8","author":"KY Liu","year":"2021","unstructured":"Liu KY, Schneider LS, Howard R. The need to show minimum clinically important differences in Alzheimer's disease trials. Lancet Psychiatry. 2021;8:1013\u20136.","journal-title":"Lancet Psychiatry."},{"key":"1141_CR99","first-page":"211","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C, et al. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis. 2022;9:211\u201320.","journal-title":"J Prev Alzheimers Dis."},{"key":"1141_CR100","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JAD-130029","volume":"37","author":"K Magnusson","year":"2013","unstructured":"Magnusson K, Sehlin D, Syv\u00e4nen S, Svedberg MM, Philipson O, S\u00f6derberg L, et al. Specific uptake of an amyloid-\u03b2 protofibril-binding antibody-tracer in A\u03b2PP transgenic mouse brain. J Alzheimers Dis. 2013;37:29\u201340.","journal-title":"J Alzheimers Dis."},{"key":"1141_CR101","doi-asserted-by":"publisher","first-page":"10759","DOI":"10.1038\/ncomms10759","volume":"7","author":"D Sehlin","year":"2016","unstructured":"Sehlin D, Fang XT, Cato L, Antoni G, Lannfelt L, Syv\u00e4nen S. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease. Nat Commun. 2016;7:10759.","journal-title":"Nat Commun."},{"issue":"17","key":"1141_CR102","doi-asserted-by":"publisher","first-page":"17490","DOI":"10.1074\/jbc.M311300200","volume":"279","author":"B O'Nuallain","year":"2004","unstructured":"O\u2019Nuallain B, Williams AD, Westermark P, Wetzel R. Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem. 2004;279(17):17490\u20139.","journal-title":"J Biol Chem."},{"key":"1141_CR103","doi-asserted-by":"publisher","first-page":"848215","DOI":"10.3389\/fnins.2022.848215","volume":"16","author":"GA Krafft","year":"2022","unstructured":"Krafft GA, Jerecic J, Siemers E, Cline EN. ACU193: an immunotherapeutic poised to test the amyloid \u03b2 oligomer hypothesis of Alzheimer's disease. Front Neurosci. 2022;16:848215.","journal-title":"Front Neurosci."},{"key":"1141_CR104","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1038\/s41598-018-22979-2","volume":"8","author":"X Wang","year":"2018","unstructured":"Wang X, Kastanenka KV, Arbel-Ornath M, Commins C, Kuzuya A, Lariviere AJ, et al. An acute functional screen identifies an effective antibody targeting amyloid-\u03b2 oligomers based on calcium imaging. Sci Rep. 2018;8:4634.","journal-title":"Sci Rep."},{"key":"1141_CR105","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1038\/emboj.2010.211","volume":"29","author":"I Kuperstein","year":"2010","unstructured":"Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, et al. Neurotoxicity of Alzheimer's disease A\u03b2 peptides is induced by small changes in the A\u03b242 to A\u03b240 ratio. EMBO J. 2010;29:3408\u201320.","journal-title":"EMBO J."},{"key":"1141_CR106","doi-asserted-by":"publisher","first-page":"279","DOI":"10.14573\/altex.1310071","volume":"31","author":"SE Cavanaugh","year":"2014","unstructured":"Cavanaugh SE, Pippin JJ, Barnard ND. Animal models of Alzheimer disease: historical pitfalls and a path forward. ALTEX. 2014;31:279\u2013302.","journal-title":"ALTEX."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01141-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01141-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01141-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T17:33:35Z","timestamp":1701624815000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01141-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01141-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments for primary cell culture were in accordance with institutional and Dutch governmental guidelines and regulations and were approved by the Animal Ethical Committee of the VU University\/VU University Medical Centre. Human brain tissue was obtained from the Netherlands Brain Bank, and informed consent for research purposes is available for each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS owns shares in, and is a full-time employee of, Alzinova AB, which owns the intellectual property of the antibodies ALZ-201 and chALZ-201. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}